Research location
Safety Harbor
Florida, United States
Advertisement
Research activity in Safety Harbor
Florida, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 67 trials and 67 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Safety Harbor
67 linked trials · page 1 of 2A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 · 2026-05-11 · 1 site observation
RECRUITING
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabNCT06876714 · 2025-09-17 · 1 site observation
RECRUITING
SPYRAL GEMINI Pilot StudyNCT06907147 · 2025-05-01 · 1 site observation
RECRUITING
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of HypertensionNCT06559891 · 2024-10-03 · 1 site observation
RECRUITING
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionNCT06307652 · 2024-04-12 · 1 site observation
RECRUITING
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerNCT06058377 · 2023-11-27 · 1 site observation
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 1 site observation
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerNCT05929768 · 2023-09-15 · 1 site observation
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 1 site observation
RECRUITING
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionNCT05334069 · 2022-08-18 · 1 site observation
RECRUITING
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy ProductsNCT00271180 · 1983-01-01 · 1 site observation
RECRUITING
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation
SUSPENDED
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer SurvivorsNCT05896189 · 2024-02-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)NCT05093933 · 2021-11-02 · 1 site observation
COMPLETED
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTNNCT05198674 · 2021-10-20 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT TrialNCT04847557 · 2021-04-20 · 1 site observation
COMPLETED
Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of HyperkalaemiaNCT04864795 · 2021-04-19 · 1 site observation
COMPLETED
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · 2021-03-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Personalized Therapy Study - HFRS (TriageHF) Post Approval StudyNCT04489225 · 2020-08-01 · 1 site observation
ACTIVE_NOT_RECRUITING
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyNCT04266249 · 2020-03-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Investigate CSL112 in Subjects With Acute Coronary SyndromeNCT03473223 · 2018-03-21 · 1 site observation
COMPLETED
Personalized Therapy Study - Attain Stability Quad Post-Approval StudyNCT04024943 · 2017-08-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Personalized CRT - MPP Post Approval StudyNCT03232944 · 2017-07-05 · 1 site observation
COMPLETED
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)NCT03071692 · 2017-03-23 · 1 site observation
TERMINATED
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)NCT03057951 · 2017-03-02 · 1 site observation
COMPLETED
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart FailureNCT02787044 · 2016-08-01 · 1 site observation
COMPLETED
Attain Performa™ Left Ventricular (LV) Quadripolar Leads Chronic Performance StudyNCT02294331 · 2014-08-01 · 1 site observation
COMPLETED
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk FactorsNCT02019264 · 2014-01-24 · 1 site observation
COMPLETED
The Product Surveillance Registry REVERSE Post Approval StudyNCT01660035 · 2012-04-01 · 1 site observation
COMPLETED
Personalized CRT - PSRNCT03723265 · 2012-01-01 · 1 site observation
COMPLETED
Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsNCT01495702 · 2011-12-01 · 1 site observation
COMPLETED
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsNCT01475838 · 2011-11-01 · 1 site observation
COMPLETED
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic VirusNCT01338883 · 2011-06-01 · 1 site observation
COMPLETED
Model 4296 Left Ventricular (LV) Lead Chronic Performance StudyNCT01361672 · 2011-05-01 · 1 site observation
COMPLETED
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsNCT01309243 · 2011-02-01 · 1 site observation
COMPLETED
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DFNCT01252940 · 2010-11-01 · 1 site observation
COMPLETED
Pilot Assessment of Lopinavir/Ritonavir and MaravirocNCT00981318 · 2009-12-01 · 1 site observation
TERMINATED
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected PatientsNCT00782301 · 2009-03-01 · 1 site observation
WITHDRAWN
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus RaltegravirNCT00708162 · 2008-07-01 · 1 site observation
COMPLETED
Safety and Efficacy Study of Switching From Epzicom to TruvadaNCT00724711 · 2008-07-01 · 1 site observation
COMPLETED
Prospective Observational Epidemiologic Study of Maraviroc's SafetyNCT00665561 · 2008-03-31 · 1 site observation
COMPLETED
A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)NCT00524368 · 2007-10-01 · 1 site observation
COMPLETED
A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected PatientsNCT00488059 · 2007-06-01 · 1 site observation
TERMINATED
Expanded Access Program for Maraviroc At Multiple CentersNCT00426660 · 2007-02-01 · 1 site observation
COMPLETED
A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra RiskNCT00412113 · 2007-01-01 · 1 site observation
COMPLETED
Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected PatientsNCT00365612 · 2006-07-01 · 1 site observation
COMPLETED
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure TrialNCT00358215 · 2006-06-01 · 1 site observation
COMPLETED
Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) NeuropathyNCT00264875 · 2006-02-01 · 1 site observation
COMPLETED
TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.NCT00254046 · 2005-11-01 · 1 site observation
COMPLETED
Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected SubjectsNCT00262522 · 2005-11-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.